Century Therapeutics (NASDAQ:IPSC – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Century Therapeutics to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.
Insider & Institutional Ownership
50.2% of Century Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 2.4% of Century Therapeutics shares are held by insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Century Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Century Therapeutics | N/A | -45.64% | -35.94% |
| Century Therapeutics Competitors | -12,519.20% | -215.47% | -31.42% |
Risk and Volatility
Valuation and Earnings
This table compares Century Therapeutics and its rivals gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Century Therapeutics | $109.16 million | -$9.58 million | -1.82 |
| Century Therapeutics Competitors | $702.35 million | $7.52 million | -17.98 |
Century Therapeutics’ rivals have higher revenue and earnings than Century Therapeutics. Century Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Analyst Ratings
This is a breakdown of current recommendations for Century Therapeutics and its rivals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Century Therapeutics | 1 | 2 | 4 | 0 | 2.43 |
| Century Therapeutics Competitors | 9951 | 15359 | 45765 | 1602 | 2.54 |
Century Therapeutics currently has a consensus target price of $4.75, indicating a potential upside of 307.73%. As a group, “Biotechnology” companies have a potential upside of 114.69%. Given Century Therapeutics’ higher probable upside, analysts clearly believe Century Therapeutics is more favorable than its rivals.
Summary
Century Therapeutics rivals beat Century Therapeutics on 7 of the 13 factors compared.
About Century Therapeutics
Century Therapeutics is a biotechnology company developing cell-based therapies for cancer and other serious diseases. Its research focuses on allogeneic treatments, which are designed to be produced from donor cells rather than made separately for each patient. The company uses induced pluripotent stem cell technology to create immune cells, including natural killer cells and T cells, that can be engineered to recognize and attack disease. Its work includes developing cell therapies with genetic modifications intended to improve their activity and persistence.
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
